Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Niguarda Hospital | OTHER |
Not provided
Not provided
Not provided
Not provided
The general objective of this study is to identify biomarkers of sleep quality, sarcopenia, insulin resistance, oxidative stress and inflammation associated with prefrailty in middle-aged and elderly obese subjects through the integrated study of sleep patterns, functional cardiovascular testing, olfactory function and circulating molecules.
Results from the SleSOB study will contribute to identify molecular and functional determinants of prefrailty, to allow early targeted interventions and will have important implications for empowerment of elderly citizens to self-management of preventive measures and healthy lifestyle.
Frailty, an age-related state of low physiological reserve and high vulnerability to stressors, impacts on health, functional independence, quality of life and survival; its early detection at the prefrailty stage offers the opportunity for preventive intervention. Sarcopenia, a hallmark of frailty, may occur in association with obesity and worsen functional deterioration. Obesity is strongly associated with insulin resistance and is a risk factor for both cardiometabolic diseases and cognitive impairment. Adipose tissue exerts autocrine and paracrine functions leading to chronic low-grade inflammation and increased oxidative stress that, in turn, decrease muscle density and precipitate muscle strength loss. Sleep disturbances and sarcopenia might be causally related through dysregulation of glucose metabolism and disruption of the secretory pattern of hormones involved in muscle metabolism.
Main objective:
To establish among young-elderly obese subjects the prevalence of prefrailty as defined by presence of ≥1 of reduced muscle mass, fatigue, weakness, slowness, and low physical activity (Fried's criteria)
Secondary objectives:
Study design:
Eligible subjects will attend the clinic in the morning in the fasting state to undergo
A wearable system (Win@home, CE0434) for 24 h recording of rhythm, circadian heart rate, respiratory rate and oxygen saturation, posture and physical activity will be applied to each subject for the subsequent 24 hours
Not provided
Not provided
Not provided
Not provided
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Prevalence of prefrailty | Proportion of subjects presenting with one or more of reduced muscle mass, fatigue, weakness, slowness, and low physical activity | Day one |
| Measure | Description | Time Frame |
|---|---|---|
| Prevalence of sarcopenia | Proportion of subjects presenting with reduced muscle mass (by gender-specific cut offs ) coupled with decreased muscle strength (men ≤ 32 kg, women ≤ 21 kg and/or reduced gait speed (<0.8 mt/sec on a 4 mt course) | Day one |
| Cardiometabolic risk profile: insulin resistance |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Middle-aged and young-old obese subjects will be enrolled at a specialised nutrition clinic. Subjects will be on a maintenance weight management program including lifestyle advice and diet based on the principles of the Modern Mediterranean Diet Pyramid (variety in food choices, seasonality and spices to flavor dishes). The diet is modified to avoid high caloric food and distributed in 3 main meals and 2 healthy snacks during the day to provide a caloric intake of 28-30 kcal/die/kg body weight and macronutrient breakdown as recommended by INRAN (http://www.inran.it/) (Protein 15%, Fat < 30%, carbohydrates 55/60% of which soluble 10-12 % and fiber 30 g die).
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Renata De Maria, MD | Contact | +390266101344 | renata.demaria@ospedaleniguarda.it | |
| Jonica Campolo, MSc | Contact | +39026473407 | jonica.campolo@ospedaleniguarda.it |
| Name | Affiliation | Role |
|---|---|---|
| Maria Giovanna Trivella, MD | Istituto di Fisiologia Clinica CNR | Principal Investigator |
| Jonica Campolo, MSc | Istituto di Fisiologia Clinica CNR | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Istituto di Fisiologia Clinica del CNR UOS Milano | Milan | 20162 | Italy |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D020447 | Parasomnias |
| D007333 | Insulin Resistance |
| D000857 | Olfaction Disorders |
| ID | Term |
|---|---|
| D012893 | Sleep Wake Disorders |
| D009422 | Nervous System Diseases |
| D001523 | Mental Disorders |
| D006946 | Hyperinsulinism |
Not provided
Not provided
Not provided
Not provided
Not provided
Serum, plasma and urine samples
Homeostatic Model Assessmenti (HOMA)-insulin resistance index |
| Day one |
| Cardiometabolic risk profile: fatty liver | Fatty liver index (FLI) | Day one |
| Cardiometabolic risk profile: 10-year cardiovascular risk | HeartSCORE | Day one |
| Sleep abnormalities: idiopathic REM Behaviour Disorder (iRBD) | Answer to screening question for iRBD | Day one |
| Sleep abnormalities: insomnia severity | Insomnia Severity Index (ISI) score | Day one |
| Sleep abnormalities: daytime sleepiness | Epworth Sleepiness Scale (ESS) score | Day one |
| Cardiac rhythm abnormalities | Atrial fibrillation burden during 24 hour home monitoring | Day one |
| Cardiac dysautonomia: deep breathing test | Expiratory/inspiratory ratio | Day one |
| Cardiac dysautonomia: lying to standing test | Lying-to standing ratio | Day one |
| Orthostatic hypotension | Drop ≥20 mmHg in systolic and/or ≥10 mmHg in diastolic blood pressure after 1 and 5 minutes of active standing | Day one |
| Olfactory function: Total Olfactory Score (TOS) | Sum of Olfactory Threshold, Identification, Discrimination scores | Day one |
| Screening for cognitive impairment | Mini Mental State Examination (MMSE) score | Day one |
| Tissue accumulation of Advanced Glycation End-products (AGE) | AGE Reader Score | Day one |
| Biomarkers of oxidative stress | Malondyaldehyde, aminothiols | Day one |
| Inflammatory biomarkers | Cytokinesinterleukin-6, interleukin-1beta, tumour ecrosis Factor-alpha, neopterin | Day one |
| Adipokines | Adiponectin, leptin | Day one |
| Myokines | Myostatin, irisin | Day one |
| D044882 |
| Glucose Metabolism Disorders |
| D008659 | Metabolic Diseases |
| D009750 | Nutritional and Metabolic Diseases |
| D012678 | Sensation Disorders |
| D009461 | Neurologic Manifestations |
| D012816 | Signs and Symptoms |
| D013568 | Pathological Conditions, Signs and Symptoms |